Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liraglutide + phentermine
- Development stage
- Phase 4
- Lead developer
- Novo Nordisk
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous, Oral
01
Overview
Liraglutide + phentermine is a combination of two pharmaceutical agents used off-label for weight management in adults with obesity. Liraglutide is a glucagon-like peptide 1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, delays gastric emptying, and reduces appetite. Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the central nervous system to increase norepinephrine release and reduce hunger signals. The combination has been studied in clinical trials for its potential to augment weight loss beyond what is achieved with either agent alone; however, evidence suggests only modest additional benefit when added to ongoing liraglutide therapy after significant initial weight loss[1][3][4]. Both drugs are approved individually for obesity but not as a fixed-dose combination.
- Other names
- Saxenda + Adipex-PSaxenda + Lomairaliraglutide-phentermine
02
Targets
DAT (Dopamine plasma membrane transport protein)GLP1R (GLP-1R)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on liraglutide + phentermine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liraglutide + phentermine.